South Korea Insulin Drugs Delivery Devices Market Size, Share and Outlook - Growth Analysis Report and Forecast Trends 2026-2030

South Korea's insulin delivery devices market includes a spectrum of technologies from traditional insulin pens to advanced connected and automated systems. The market's $1.75 billion valuation in 2025 reflects the convergence of digital healthcare and diabetes management within one of Asia's most developed healthcare systems. Government-backed initiatives and national diabetes management guidelines have accelerated the integration of continuous glucose monitoring and automated insulin delivery into standard clinical practice.

• •The market is expanding at a 45% annual growth rate, among the highest globally for diabetes care devices
• •Clinical guidelines from the Korean Diabetes Association support evidence-based adoption of CGM and intensive insulin delivery devices
• •Universal healthcare coverage in South Korea facilitates broad patient access to advanced insulin delivery technologies

The rising prevalence of diabetes in South Korea's aging and increasingly urbanized population is a primary catalyst for market expansion. Government programs promoting digital health innovation, combined with reimbursement policies supporting CGM and automated insulin delivery, have removed significant barriers to adoption. Advances in locally developed devices and growing clinical familiarity with automated hybrid closed-loop systems further propel demand.

• •South Korea's diabetes burden has been increasing steadily, driving demand for more precise and convenient insulin delivery solutions
• •National digital health initiatives and government-academic partnerships have supported the development and distribution of bioengineered insulin delivery devices
• •Expanding insurance coverage for CGM and insulin pump therapy has significantly improved patient access to advanced devices

The market spans insulin pens, wearable insulin pumps, continuous glucose monitors, connected smart pens, and automated insulin delivery (AID) systems, with connected and automated segments experiencing the fastest growth. Domestically manufactured devices such as the Caresens Air glucose monitoring system illustrate South Korea's growing capacity for locally developed diabetes technologies. Within the broader Asia-Pacific context, the region is projected to deliver the fastest growth in diabetes care devices through 2030, supported by expanding urban patient populations across the region.

• •Insulin pumps, connected insulin pens, and automated insulin delivery systems represent the highest-growth product categories
• •South Korea has developed locally manufactured CGM and integrated diabetes devices, reducing reliance on imports
• •Asia-Pacific is positioned for the fastest regional growth in diabetes care devices through 2030

What are the recent trends and outlook?

The market is trending toward fully integrated, AI-powered diabetes management platforms that seamlessly connect CGM data with automated insulin delivery. Hybrid closed-loop systems are gaining clinical momentum following evidence of improved glycemic outcomes in both children and adults. Continued investment in digital health infrastructure and smart healthcare applications is expected to sustain the market's 45% growth trajectory through the forecast period.

• •Integration of AI and IoT technologies is driving the development of smarter, more autonomous insulin delivery systems
• •Clinical adoption of automated hybrid closed-loop systems is expanding as evidence for efficacy and patient outcomes grows
• •Stakeholder collaboration among government, healthcare providers, and device manufacturers is accelerating the endorsement and deployment of digitally connected subcutaneous drug delivery systems